Melazyme, a precision fermentation startup focused on functional biomolecules, has raised $2 million in a seed funding round led by SeaX Ventures, with participation from Stellaris Venture Partners and Plug and Play Ventures.

In a statement on Thursday, Thailand-based SeaX Ventures said the funding can support platform development, scale production, and advance early commercial deployments across its portfolio of target molecules.

Founded in 2025, the United States-based Melazyme focuses on fermentation-derived specialty proteins, including brazzein, which is already being developed with commercial partners. Melazyme is also expanding into other high-value molecules where fermentation can offer advantages over conventional chemical processes.

Its technology enables commercially viable production of melanin with adjustable functional properties tailored for different applications, according to Melazyme. Near-term commercial efforts are focused on the cosmetics sector, while Melazyme is already engaging with global manufacturers interested in melanin’s UV protection and pigmentation properties.

SeaX Ventures Managing Partner Dr. Kid Parchariyanon said the founding team can bring about experience in building and scaling precision fermentation companies and described the platform as having applications beyond a single industry. The newly raised capital will also support partner collaborations and early deployments across consumer, industrial, and environmental markets.

Southeast Asia-focused SeaX Ventures invests $10M in RyboDyn’s AI-driven cancer research